Table 4 Mean urinary (±SD) concentrations and clinical associations of 10 biomarkers in cohort #2 assessed by Multi-Array assay
From: A multiplex immunoassay for the non-invasive detection of bladder cancer
Total bladder cancer (50 %), n = 100 | Low-grade bladder cancer (21 %), n = 21 | High-grade bladder cancer (79 %), n = 79 | NMIBC (58 %), n = 58 | MIBC (42 %), n = 42 | Total controls (50 %), n = 100 | |
|---|---|---|---|---|---|---|
IL8 (pg/ml)*, ^, + | 761.6 ± 804.4 | 348.3 ± 541.8 | 871.5 ± 829.4 | 593.2 ± 766.8 | 994.3 ± 805.9 | 122.8 ± 380.1 |
MMP9 (ng/ml)*, + | 115.7 ± 392.9 | 26.0 ± 61.0 | 139.6 ± 438.4 | 89.0 ± 362.1 | 152.6 ± 433.6 | 2.8 ± 11.7 |
A1AT (ng/ml)*, + | 4002.6 ± 7384.7 | 2961.5 ± 7204.7 | 4279.4 ± 7452.3 | 3949.8 ± 8302.9 | 4075.6 ± 5985.6 | 993.6 ± 2962.6 |
ANG (pg/ml)*, + | 6501.0 ± 23,967.9 | 10,109.0 ± 42,456.3 | 5541.9 ± 16,201.7 | 6567.1 ± 27,404.6 | 6409.7 ± 18,520.3 | 619.0 ± 1093.1 |
VEGFA (pg/ml)*, + | 1321.0 ± 1969.9 | 971.0 ± 1747.0 | 1414.1 ± 2025.0 | 1082.0 ± 1832.9 | 1651.1 ± 2122.9 | 570.4 ± 586.8 |
CA9 (pg/ml)* | 168.6 ± 461.9 | 126.9 ± 398.6 | 179.7 ± 479.0 | 142.9 ± 409.9 | 204.1 ± 528.6 | 1.0 ± 0.0 |
MMP10 (pg/ml)*, ^, + | 2576.3 ± 12,512.1 | 977.4 ± 3490.8 | 3001.3 ± 13,953.7 | 1444.5 ± 5444.0 | 4139.2 ± 18,234.5 | 5.0 ± 0.0 |
APOE (pg/ml)* | 199,003.5 ± 587,474.7 | 202,108.4 ± 695,029.2 | 198,178.2 ± 560,516.7 | 266,463.1 ± 751,668.8 | 105,845.1 ± 180,362.0 | 21,654.7 ± 37,121.9 |
PAI1 (ng/ml)*, ^, + | 26.2 ± 53.7 | 12.4 ± 43.8 | 29.9 ± 55.7 | 17.6 ± 47.8 | 38.1 ± 59.5 | 0.7 ± 3.8 |
SDC1 (pg/ml) | 14,853.3 ± 43,824.9 | 9958.5 ± 9625.1 | 16,154.4 ± 49,048.9 | 10,814.6 ± 15,586.0 | 20,430.5 ± 65,153.2 | 10,459.7 ± 14,248.5 |